Detection of disseminated tumor cells in locally advanced breast cancer patients before primary systemic therapy

Breast

Volumn 22, Issue 5, 2013, Pages 908-913

  Solá, Montserrat ^a   Margelí, Mireia ^a   Castellá, Eva ^a   Cirauqui, Beatriz ^a   Mariscal, Antonio ^a   Rull, Miquel ^a   Julian, Juan F ^a   Luna, Miquel ^a   Vallejo, Virginia ^a   Fraile, Manuel ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Bone marrow; Disseminated tumor cells; Locally advanced breast cancer; Neoadjuvant chemotherapy; Primary systemic therapy

Indexed keywords

ANTHRACYCLINE; ANTIBODY; ESTROGEN RECEPTOR; FICOLL; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTICLE; BONE MARROW BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LOCALLY ADVANCED BREAST CANCER; METASTASIS; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR VOLUME;

BONE MARROW; CIRCULATING TUMOR CELLS; COMPLETE CLINICAL RESPONSE; CR; CTC; DCIS; DFS; DISEASE-FREE SURVIVAL; DISSEMINATED TUMOR CELLS; DTC; DUCTAL CARCINOMA IN SITU; INTERNATIONAL SOCIETY OF HEMATOTHERAPY AND GRAFT ENGINEERING; ISHAGE; LABC; LOCALLY ADVANCED BREAST CANCER; NEOADJUVANT CHEMOTHERAPY; ODDS RATIO; OR; OS; OVERALL SURVIVAL; PRIMARY SYSTEMIC THERAPY; PRIMARY SYSTEMIC TREATMENT; PST; RELATIVE RISK; RR;

ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC CELLS, CIRCULATING; RADIOTHERAPY, ADJUVANT; TAXOIDS;

EID: 84884166818     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.04.014     Document Type: Article

References (34)

1. Hortobagyi G.N., Singletary S.E., McNeese M.D. Treatment of locally advanced and inflammatory breast cancer. Diseases of the breast 1996, 585. Lippincot-Raven, Philadelphia. J.R. Harris (Ed.).
2. Charfare H., Limongelli S., Purushotam A.D. Neoadjuvant chemotherapy in breast cancer. Br J Surg 2005, 92:14-23.
3. Burcombe R.J., Makris A., Richman P.I., Daley F.M., Noble S., Pittam M., et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 2005, 92:147-155.
4. Giardini G., Chini C., Vallini I., Pinotti G. Biological marker modifications in primary breast cancer submitted to neoadjuvant chemotherapy and correlation with response. Breast 2001, 10:S36.
5. Colleoni M., Gelber S., Coates A.S., Castiglione-Gertsch M., Gelber R.D., Price K., et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. JClin Oncol 2001, 19:4141-4149.
6. Amat S., Penault-Llorca F., Cure H., Le Bouedëc G., Achard J.L., Van Praagh I., et al. Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 2002, 20:791-796.
7. Feldman L.D., Hortobagyi G.N., Buzdar A.U., Ames F.C., Blumenschein G.R. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986, 46:2578-2581.
8. Braun S., Vogl F.D., Naume B., Janni W., Osborne M.P., Coombes R.C., et al. Apooled analysis of bone marrow micrometastasis in breast cancer. NEngl J Med 2005, 353:793-802.
9. Fetsch P., Cowan K.H., Weng D.E., Freifield A., Filie A.C., Abati A. Detection of circulating tumor cells and micrometastases in stage II, III and IV breast cancer patients utilizing cytology and immunocytochemistry. Diagn Cytopathol 2000, 22:323-328.
10. Wiedswang G., Borgen E., Kåresen R., Kvalheim G., Nesland J.M., Qvist H., et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. JClin Oncol 2003, 21:3469-3478.
11. Gebauer G., Fehm T., Merkle E., Beck E.P., Lang N., Jäger W. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. JClin Oncol 2001, 19:3669-3674.
12. Braun S., Pantel K., Müller P., Janni W., Hepp F., Kentenich C.R., et al. Cytokeratin-positive cells in the bone marrow and survival of patients in stage I, II or III breast cancer. NEngl J Med 2000, 342:525-533.
13. Mansi J.L., Gogas H., Bliss J., Gazet J.C., Berger U., Coombes R.C. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 1999, 354:197-202.
14. Diel I.J., Kauffmann M., Costa S.D., Holle R., von Minckwitz G., Solomayer E.F., et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. JNatl Cancer Inst 1996, 88:1652-1658.
15. Hall C., Krishnamurthy S., Lodhi A., Bhattacharyya A., Anderson A., Kuerer H., et al. Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. Cancer 2012, 18:342-348.
16. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. JNatl Cancer Inst 2000, 92:205-216.
17. Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999, 1:377-388. The European ISHAGE Working Group for Standardization of Tumor Cell Detection.
18. Solá M., Margelí M., Castellá E., Julian J.F., Rull M., Gubern J.M., et al. Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: a prospective observational study. BMC Cancer 2011, 11:252.
19. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Untch M., Smith I., Gianni L., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEngl J Med 2005, 353:1659-1672.
20. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. NEngl J Med 2005, 353:1673-1684.
21. Hall C., Krishnamurthy S., Lodhi A., Mosalpuria K., Kuerer H.M., Meric-Bernstam F., et al. Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol 2010, 17:3252-3258.
22. Becker S., Solomayer E., Becker-Pergola G., Wallwiener D., Fehm T. Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Breast Cancer Res Treat 2007, 106:239-243.
23. Redding W.H., Coombes R.C., Monaghan P., Clink H.M., Imrie S.F., Dearnaley D.P., et al. Detection of micrometastases in patients with primary breast cancer. Lancet 1983, 2:1271-1274.
24. Diel I.J., Cote R.J. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer. Cancer Treat Rev 2000, 26:53-65.
25. Janni W., Rack B., Schindlbeck C., Strobl B., Rjosk D., Braun S., et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 2005, 103:884-891.
26. Cote R.J., Rosen P.P., Lesser M.L., Old L.J., Osborne M.P. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. JClin Oncol 1991, 9:1749-1756.
27. Braun S., Kentenich C., Janni W., Hepp F., de Waal J., Willgeroth F., et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. Clin Oncol 2000, 18:80-86.
28. Czerkinsky C., Moldoveanu Z., Mestecky J., Nilsson L.A., Ouchterlony O. Anovel two colour ELISPOT assay. I. Simultaneous detection of distinct types of antibody-secreting cells. JImmunol Methods 1988, 115:31-37.
29. Liu R., Wang X., Chen G.Y., Dalerba P., Gurney A., Hoey T., et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. NEngl J Med 2007, 356:217-226.
30. Vincent-Salomon A., Pierga J.Y., Couturier J., Couturier J., d'Enghien C.D., Nos C., et al. HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?. Br J Cancer 2007, 96:654-659.
31. Solomayer E.F., Becker S., Pergola-Becker G., Bachmann R., Krämer B., Vogel U., et al. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat 2006, 98:179-184.
32. Braun S., Schlimok G., Heumos I., Schaller G., Riethdorf L., Riethmüller G., et al. Erb-B2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 2001, 61:1890-1895.
33. Fehm T., Hoffmann O., Aktas B., Becker S., Solomayer E.F., Wallwiener D., et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009, 11:R59.
34. Allan A.L., Keeney M. Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. JOncol 2010, 2010:426218.